Belite Bio, Inc (BLTE)

$30.43

+0.45 (+1.50%)
Rating:
Recommendation:
-
Symbol BLTE
Price $30.43
Beta 0.000
Volume Avg. 0.01M
Market Cap 756.715M
Shares () -
52 Week Range 8.8-44.7
1y Target Est -
DCF Unlevered BLTE DCF ->
DCF Levered BLTE LDCF ->
ROE -
ROA -
Operating Margin -
Debt / Equity -
P/E -
P/B -
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest BLTE news


Healthcare
Biotechnology
NASDAQ Capital Market

Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.